{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106102","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.312374+00:00","generated_at":"2026-06-10T05:57:21.639567+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Theriva Biologics announces 2023 annual meeting voting results; directors elected, auditor ratified","bullets":["Four directors elected: Kraws, Shallcross, Monahan, Wolf; votes for ranged from 1,996,551 to 2,553,173, with 4,077,933 broker non-votes each.","Ratification of BDO USA P.C. as independent auditor for FY 2023: 7,059,989 for, 171,037 against, 182,495 abstentions.","Meeting held October 2, 2023; no other proposals voted on."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106102","json":"https://secwatch.observer/filing/0001104659-23-106102.json","markdown":"https://secwatch.observer/filing/0001104659-23-106102.md","text":"https://secwatch.observer/filing/0001104659-23-106102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465923106102/0001104659-23-106102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465923106102/tm2327462d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:57:21.639567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a9ce9f64e420f32e71b2bf90da6897b26d79e34","claim":"Theriva Biologics, Inc. shareholders approved Ratification of the appointment of BDO USA P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-10-02 meeting.","evidence_excerpt":"Proposal 2 — Ratification of the appointment of BDO USA P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The stockholders ratified and approved the appointment","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465923106102/0001104659-23-106102-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-02"}],"fact_type":"shareholder_vote"},{"claim_id":"9ed37cd4ff4c632e3b6d3744069a1e7981390e75","claim":"Theriva Biologics, Inc. shareholders approved Election of Directors at the 2023-10-02 meeting.","evidence_excerpt":"Proposal 1 — Election of Directors . The following four (4) individuals were elected as directors","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465923106102/0001104659-23-106102-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}